Drug Profile
Fosmanogepix - Basilea Pharmaceutica
Alternative Names: APX-001; E-1211; E-210; PF-07842805Latest Information Update: 08 Jan 2024
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Developer Amplyx Pharmaceuticals
- Class Aminopyridines; Antifungals; Antineoplastics; Oxazoles; Phosphates; Small molecules
- Mechanism of Action GWT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Aspergillosis; Candidaemia
- Phase I Mycoses
- No development reported Acute myeloid leukaemia; Coccidioidomycosis